February 25, 2025 12:47 PM ESTUpdated 01:27 PM
Pharma
Law

J&J seeks to stop Sam­sung Bioepis from li­cens­ing Ste­lara biosim­i­lar

Ayisha Sharma

News Reporter

John­son & John­son is su­ing Sam­sung Bioepis for al­leged­ly breach­ing the terms of a con­tract re­gard­ing the launch of the Ko­re­an biotech’s Ste­lara biosim­i­lar. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Lil­ly pays $10M up­front for Organo­vo’s FXR ag­o­nist pro­gram

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

Re­pare to lay off 75% of staff; Cas­tle Creek inks $75M roy­al­ty deal

Hims eyes growth in its weight loss busi­ness, de­spite end of semaglu­tide short­age

Al­ny­lam eyes big­ger dis­eases in more tis­sue types at ‘in­flec­tion point’ for siR­NA

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times